Background: There are insufficient data regarding how to deal with moderate aortic valve (AV) dysfunction during rheumatic mitral valve (MV) surgery. In this study, the clinical outcomes of patients ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

BACKGROUND: Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells.

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) revealed promising new findings on its atrioventricular ...

This educational review will oversee LVT pathophysiology, current status of the guidelines-recommended echocardiographic approach and the role of multimodality imaging, as well as prevention and ...

Orchestra BioMed (OBIO) announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation therapy on ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

This study evaluated the prognostic value of a novel echocardiographic cardiac damage classification system for patients with moderate or severe AFMR. Methods In a retrospective multicentre study, ...